INTRODUCTION
Leptin, the product of the ob gene discovered in 1994, 1 not only controls body weight and energy expenditure, but may also exert pleiotropic effects on multiple organs outside the central nervous system. In particular, accumulating evidence suggests that leptin affects cardiovascular homeostasis. 2 For example, the hormone has been found to increase platelet activity, 3 to promote the formation of arterial thrombi 4 --6 and to induce oxidative stress in endothelial cells. 7 In vivo, leptin administration promoted the growth of vascular lesions in leptin-deficient ob/ob mice in a receptor-specific manner. 8 However, apart from its potential 'proatherogenic' role, leptin may also exert protective effects, such as the induction of nitric oxide production, 9 the reduction of infarct size during early reperfusion 10 and the promotion of vascular regeneration. 11, 12 In humans, the impact of leptin on thrombosis and coronary artery disease is still controversial. In the prospective West of Scotland Coronary Prevention Study in moderately hypercholesterolemic men, leptin levels were higher in those who subsequently developed coronary artery disease during 5-year-follow-up. 13 Furthermore, in patients with known coronary artery disease, leptin was an independent predictor of future cardiovascular events. 14 On the other hand, the possible impact of leptin on venous thromboembolism has not been directly studied thus far. A higher body mass index (BMI) was associated with higher incidence rates of venous thromboembolism, 15 and it is known that leptin levels correlate with BMI as a consequence of central leptin resistance. 16, 17 In addition, leptin correlated with higher values of insulin, 18 triglycerides and systolic blood pressure, 19 that is, findings of the metabolic syndrome, which is more common in patients with idiopathic deep vein thrombosis than in controls. 20 In a mouse model of induced venous thromboembolism, a leptin-neutralizing antibody significantly reduced the number of occlusive thrombi in pulmonary vessels and improved survival. 5 Taken together, these data suggest that leptin might, directly or indirectly, influence the pathophysiology of venous thromboembolism by enhancing the thrombotic process. We therefore investigated the relationship between leptin levels and clinical outcome, over the short and long term, in a prospective cohort study of 264 consecutive patients with acute pulmonary embolism (PE).
MATERIALS AND METHODS

Patient population and study design
We prospectively followed consecutive patients with acute symptomatic PE (symptom onset, p4 weeks) at the University Hospital of Goettingen between 2003 and 2009. PE was diagnosed by contrast-enhanced computed tomography pulmonary angiography (n ¼ 200), perfusion lung scan (n ¼ 55) or conventional pulmonary angiography (n ¼ 5); some patients underwent more than one diagnostic approach. In 16 hemodynamic unstable patients, the diagnosis was based on clinical presentation and on the presence of right ventricular dysfunction on echocardiography. Right ventricular dysfunction was defined as dilatation of the right ventricle (end-diastolic diameter 430 mm from the parasternal view, or the right ventricle appearing larger than the left ventricle from the subcostal or apical view) combined with right atrial hypertension (absence of inspiratory collapse of the inferior vena cava) in the absence of left ventricular or mitral valve disease. Of 212 patients (80% of the study population) who underwent cardiac ultrasound, 104 (39%) were diagnosed with right ventricular dysfunction.
Blood was drawn immediately for measurement of baseline (admission) biomarker levels before further diagnostic workup. Following confirmation of the diagnosis, patients were asked to sign the informed consent form. Subsequently, complete data on baseline clinical, hemodynamic and laboratory parameters were obtained using a standardized questionnaire by investigators unaware of the patients' biomarker levels.
Clinical follow-up data for 30 days were obtained from all patients included in the study. A complicated 30-day outcome was defined as death or at least one of the following major adverse events: (1) need for catecholamine administration (except for dopamine at a rate of o5 mg kg À1 min À1 ) to maintain adequate tissue perfusion and prevent or treat cardiogenic shock; (2) endotracheal intubation; or (3) cardiopulmonary resuscitation. Long-term survival was assessed by follow-up examinations at 6-month intervals after PE diagnosis. Leptin levels were not communicated to the clinicians involved in the care of the study patients, and they were not used to guide patient management or to monitor the effects of treatment during the hospital stay or at any time during the follow-up period. The study protocol was approved by the Ethics committee of the University of Gö ttingen.
Laboratory parameters and biomarker testing
Venous plasma and serum samples were collected on admission and immediately stored at À80 1C. Samples were later analyzed in batches after a single thaw. Plasma leptin levels were measured by a quantitative sandwich immunoassay technique (R&D Systems, Minneapolis, MN, USA). Cardiac troponin T and N-terminal pro-B-type natriuretic peptide levels were determined in plasma samples using quantitative electrochemiluminescence immunoassays (Elecsys 1010/2010 analyzer, Roche Diagnostics, Mannheim, Germany) as described. 21, 22 All other laboratory measurements were performed at the Department of Clinical Chemistry, University of Goettingen, using standard laboratory techniques. Renal insufficiency was defined as a glomerular filtration rateo60 ml min À1 per 1.73 m 2 . The glomerular filtration rate was calculated from the 'four-variable' Modification of Diet in Renal Disease Study equation. 23 
Statistical analysis
Using the modified Kolmogorov --Smirnov test (Lilliefors test), the continuous variables tested in the present study were found not to follow a normal distribution; therefore, they were presented as medians with corresponding 25th and 75th percentiles and were compared using the unpaired Mann --Whitney U-test. Receiver operating curve analysis was used to determine the area under the curve for leptin with regard to a complicated 30-day course. Categorical variables were compared using Fisher's exact test. Univariable logistic regression was performed to calculate odds ratios (OR) with the corresponding 95% confidence intervals for a 30-day-complicated course. To identify predictors of long-term mortality, Cox's proportional hazards regression analysis was performed using Wald's test; these results are presented as hazard ratios with corresponding 95% confidence intervals. Survival rates were estimated by the Kaplan --Meier method, and statistical comparison was performed using the log-rank test. For parameters with established cut-off values, variables were dichotomized according to their specific thresholds. A positive test was considered for troponin T 40.03 ng ml À1 , and for N-terminal pro-B-type natriuretic peptide X1000 pg ml
À1
. There is no established reference value for leptin. Thus, leptin was used as a continuous variable and standardized after logarithmic transformation to correct its skewed distribution. In addition, ORs were calculated for tertiles of leptin at baseline for the whole population and for gender-specific differences. All tests were two-sided and used a significance level of 0.05. All analyses were performed using the SPSS 17.0 software (SPSS Inc., IBM Deutschland GmbH, Ehningen, Germany) and GraphPad Prism 4 (GraphPad Software, La Jolla, CA, USA).
RESULTS
Early outcome
The baseline clinical parameters, laboratory values and outcome measures of the study population are shown in Table 1 
Patients with major complications over the first 30 days (n ¼ 49; 18.6%) had significantly higher values of troponin, N-terminal probrain natriuretic peptide, glucose, C-reactive protein and leukocytes, and lower glomerular filtration rate values compared with those with a favorable outcome ( Table 1) . Of note, BMI was not correlated with prognosis over the first 30 days (P ¼ 0.46). On the other hand, leptin levels were significantly lower in patients suffering complications (median, 5.3 ng ml À1 (1.8 --19.7) compared with patients with an uncomplicated course (10.4 ng ml À1 (4.7--25.5), P ¼ 0.02). Receiver operating characteristic analysis further suggested that lower leptin levels were associated with an unfavorable 30-day outcome with an area under the curve of 0.39 (95% confidence interval, 0.30 --49). As shown in Table 2 , when leptin was analyzed as a continuous variable, there was a significant increase in the relative risk for early complications for every decrease in the natural logarithm of leptin by one s.d. (OR 1.36 (1.06 --1.76), P ¼ 0.017; Table 2 ). Importantly, this effect was independent of BMI (OR for ln leptin adjusted by BMI; 1.52 (IQR, 1.13 --2.05), P ¼ 0.006) and of age (OR for ln leptin adjusted by age; 1.36 (IQR, 1.05 --1.76), P ¼ 0.018).
Interestingly, men appeared to have a higher risk for a poor short-term outcome with decreasing leptin levels compared to women (OR for ln leptin for men, 3.47 (1.53 --7.88), P ¼ 0.003; and for women, 1.41 (1.05 --1.90), P ¼ 0.022). The effect remained independent of BMI and age in both genders (BMI-adjusted OR for men, 3.46 (1.49 --7.80), P ¼ 0.004; and for women, 1.71 (1.18 --2.48), P ¼ 0.005; age-adjusted OR for men, 3.31 (1.44 --7.68), P ¼ 0.005; and for women, 1.44 (1.07 --1.93), P ¼ 0.017).
We classified patients into three groups, based on the tertiles of their leptin values (tertile 1, leptin o5.47 ng ml À1 ; tertile 2, leptin 5.47 --18.6 ng ml À1 ; tertile 3, leptin 418.6 ng ml
À1
). The three patient groups did not differ significantly with regard to age, clinical symptoms, history of malignant tumors, natriuretic peptide or troponin levels, markers of inflammation, or glomerular filtration rate (Table 3) ; however, there were more women in the third (highest) leptin tertile, corresponding to the higher median leptin values in women compared with men. Patients within the lowest leptin tertile had a 2.8-(IQR, 1.3 --6.1) and 2.3-fold (IQR, 1.1 --4.8) increased risk for 30-day complications compared with those in the middle and high leptin tertile, respectively (P ¼ 0.011 for comparison of tertile 1 vs 2; P ¼ 0.030 for tertile 1 vs 3). This difference appeared to be most pronounced for men with leptin levels within the lowest tertile; these patients had a 6.5-(1.4 --33.8, P ¼ 0.019) and 14-fold (1.7 --116.5, P ¼ 0.015) increased risk for short-term complications compared with men in the middle and high leptin tertile, respectively (Figure 1 ). In women, the risk was also elevated for patients in the lowest compared with the middle and highest tertile, albeit to a lesser extent (OR, 2.6 (1.04 --6.5), P ¼ 0.042; and 2.5 (1.01 --6.3), P ¼ 0.048, respectively; Figure 1 ). Of note, no differences were observed in the entire study population between patients in the middle and those in the highest leptin tertile with regard to the risk of 30-day complications (P ¼ 0.661).
Long-term outcome Patients were followed for a median period of 742 days (IQR, 227 --1298). Overall mortality was 28% (n ¼ 73). The major cause of death was malignant disease (n ¼ 26) and death related to PE (n ¼ 24; all patient died within 30 days). Two patients died due to recurrence of PE. In 13 patients, the cause of death was neither related to malignancy, nor to PE (e.g., infection, cardiac disease) and in 8 patients, the cause of death remains unknown.
Baseline leptin values were lower in patients who died during the follow-up period compared with survivors (median value, 7.8 (2.4 --20.6) vs 10.4 (4.7 --28.4) ng ml À1 , P ¼ 0.045); again, no differences were observed with regard to BMI (P ¼ 0.546). Leptin levels were not statistically different in patients with malignancy, who died during follow-up (median value, 9.0 (2.3 --21) ng ml À1 ) compared with patients with other causes of death (7.0 (2.3 --20.5) ng ml À1 , P ¼ 0.908), and compared with patients with malignant disease, who survived the follow-up period (6.9 (2.3 --15.3) ngÀml
, P ¼ 0.636). Kaplan --Meier analysis revealed that the probability of survival was lowest within the patient group defined by the lowest leptin tertile (P ¼ 0.018; Figure 2 , upper panel). Survival curves were overlapping between patients of the medium and high leptin tertile. This was particular the case in men (Figure 2 , lower right panel). In women, the probability of long-term survival separated better between the leptin tertiles with the best survival for patients of the highest leptin tertile, at least for the first 4 follow-up years ( Figure 2 , lower left panel).
DISCUSSION
In this prospective cohort study of 264 patients with acute PE, low baseline leptin levels were associated with a poor short-and longterm outcome. This finding was unexpected in view of the prothrombotic effects of leptin in experimental studies, 3 --6 and of observations suggesting that leptin levels might be an independent predictor for morbidity and mortality in patients with coronary artery disease. 13, 14 Moreover, high leptin levels have Leptin levels and outcome in pulmonary embolism C Dellas et al previously been associated with ischemic and non-ischemic stroke and reportedly were an independent predictor for future stroke events. 24, 25 As venous thromboembolism and arterial thrombosis share common risk factors such as obesity, the existing data appeared to support the assumption that higher leptin levels might be associated with a higher prothrombotic activity and worse outcome in PE patients.
The results of the present study underline the complex functions of the adipocytokine leptin within the cardiovascular system. Indeed, our findings, although unexpected, do agree with some previous reports. In a recent prospective study of nearly 1000 outpatients with stable coronary artery disease, low leptin levels were associated with a higher rate of cardiovascular events and mortality. 26 In patients with chronic kidney disease, low serum leptin concentrations were an independent predictor of mortality. 27 A protective association of high leptin values with decreased cardiovascular mortality also was reported for diabetic patients. 28 One possible explanation for our findings could be that leptin levels follow the model of 'reverse epidemiology' proposed for the relationship between excess body weight and clinical outcome. Leptin levels and outcome in pulmonary embolism C Dellas et al
In fact, although obesity is a major risk factor for hypertension, heart failure and coronary artery disease, some observational studies suggested that overweight patients with the above conditions may have a more favorable short-and long-term prognosis in the sense of an 'obesity paradox'. 29 In a large study of treated hypertensive patients with coronary artery disease, allcause mortality was 30% lower in overweight and obese patients, despite less effective blood pressure control, compared with the normal weight group. 30 A U-shaped relationship between BMI and cardiovascular mortality also was reported by another study of patients with coronary artery disease, showing excess mortality at both extremes of BMI. 31 Although the Framingham Heart Study suggests an increase of the risk for heart failure by 5 --7% for every 1 kg m À2 increment of BMI, 32 overweight and obese heart failure patients did have a reduced risk for cardiovascular and all-cause mortality. 33 The mechanisms underlying this 'paradoxical' relationship of increased body weight with cardiovascular outcomes are incompletely understood, but is has been proposed that some chronic conditions such as heart failure result in a catabolic state, and that obese patients may be protected by an increased metabolic reserve. 29 Changes in the cytokine and neuroendocrine Probability of long-term survival in patients with low (i.e., tertile 1), medium (i.e., tertile 2) and high (i.e., tertile 3) leptin levels. P-value was calculated be the log-rank test. The upper panel shows probability of long-term survival of all patients. Survival is shown for women in the lower left panel and for men in the lower right panel.
profile may also protect obese individuals in acute inflammatory conditions. 29, 33 As mentioned before, although leptin levels did correlate with BMI, the BMI itself was not a predictor of a complicated short-or long-term course, and the predictive value of leptin was independent of BMI values. However, our results are limited, as we did not assess waist circumference, a parameter known to better reflect fat mass and leptin production, and probably also predicting an adverse outcome in PE. The differences of the leptin effect in men and women (e.g., higher OR in men) may account for the BMI-independent observation and would probably be less pronounced if adjusted for parameters that better assess fat mass.
In the present study, and although leptin levels did correlate with BMI, the BMI itself was not a predictor of a complicated short-or long-term course. This finding may be because of the fact that the median BMI value was already elevated (27 (24.1 --31.2) kg m À2 ) in our study population. Alternatively, it may point towards possible direct effects of the adipocytokine on inflammatory reactions and the immune response. In fact, leptin regulates components of innate and adaptive immunity, including T-lymphocytes and monocytes, and it shares structural and functional resemblance with proinflammatory cytokines, such as interleukin-6. 34 In several studies performed in humans and mice, leptin was found to have a protective role in systemic inflammatory conditions. For example, treatment with leptin reversed the increased sensitivity to lipopolysaccharide-induced mortality in ob/ob mice. 35 Furthermore, in a sepsis model, leptin deficiency in ob/ob mice led to higher mortality and more severe organ damage, whereas systemic leptin administration improved the immune response. 36 In the rare case of human leptin deficiency, the phenotype is not only characterized by severe obesity, but also by increased frequency of infections. 37, 38 In septic patients, low leptin levels have been associated with high mortality. 39, 40 Taken together, these data indicate that leptin participates in at least some inflammatory processes and may exert protective effects through changes in immune and cytokine responses leading to better survival. The elevated expression of proinflammatory factors, such as tumor necrosis factor-a and interleukin-1b, found in a rabbit model of PE suggests an inflammatory process associated with this condition. 41 This also appears to be supported by the finding of relatively high baseline C-reactive protein levels (median, 31 mg l À1 ) and leukocyte counts (median, 9650 per ml) in our patients. In addition, patients with a complicated 30-day course after acute PE had higher baseline C-reactive protein levels and leukocyte counts in our study. Interestingly, the soluble tumor necrosis factor receptor, which is---like leptin---produced by adipocytes, appears capable of neutralizing the deleterious effects of tumor necrosis factor-a on the myocardium in patients with heart failure. 30 Patients with PE have been reported to have higher levels of this receptor compared with healthy controls. 42 Leptin may exert further protective effects within the vasculature. For example, leptin administration during reperfusion reduced infarct size in an isolated mouse heart model. 10 Leptin also enhanced the functional capacity of peripheral blood-derived human endothelial progenitor cells in vitro and improved their homing capacity in vivo.
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In conclusion, our results, which were partly unexpected, indicate that low plasma leptin concentrations are a predictor for a complicated clinical course and high mortality in patients with acute PE. The possible protective role of leptin in the pathophysiology of acute PE appeared to be independent from the patients' BMI and warrants further investigation.
